Top 3 Health Care Stocks That May Fall Off A Cliff In October

As of Oct. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Oct 16, 2026

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

Business Wire • Oct 12, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Pacira BioSciences, Inc. (NASDAQ: PCRX ) related to its sale to Viatris Inc. Under the terms of the proposed transaction, Pacira shareholders are expected to receive $36.50 in cash per share.

PRNewsWire • Oct 11, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Zacks Investment Research • Oct 9, 2026

Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion

Viatris said on Thursday ‌it will buy Pacira Biosciences for $1.65 billion, adding the ​pain therapy maker's ​products to its portfolio.

Reuters • Oct 8, 2026

Why Pacira BioSciences Skyrocketed Today

Pacira BioSciences is being bought out by Viatrias. The deal values the company at $36.50 per share or about $1.65 billion.

The Motley Fool • Oct 8, 2026

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction. Are You a PCRX Shareholder?

PRNewsWire • Oct 8, 2026

PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Pacira and its board of directors violated the.

Business Wire • Oct 8, 2026

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

Investors Business Daily • Oct 8, 2026

Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.

WSJ • Oct 8, 2026